SCHEMBL13262174

SCHEMBL13262174

CCOC(=O)c1cnc2sccc2c1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
MAPK10 P53779 1/20 0.48
ALDH1A1 P00352 2/20 0.47
LMNA P02545 2/20 0.47
HTT P42858 2/20 0.47
USP2 O75604 2/20 0.47
MAPK1 P28482 2/20 0.47
MAPT P10636 5/20 0.46
NPSR1 Q6W5P4 2/20 0.46
KDM4E B2RXH2 1/20 0.46
GLA P06280 1/20 0.46
PDE4B Q07343 1/20 0.44
TP53 P04637 1/20 0.44
RECQL P46063 1/20 0.44
HSD17B10 Q99714 1/20 0.44
GAA P10253 1/20 0.44
THRB P10828 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13262173 0.82 PDE4B (0.51) MEN1KMT2AMAPK10ALDH1A1LMNA
SCHEMBL4742620 0.79 THRB (0.64) MEN1KMT2AMAPK10ALDH1A1LMNA
SCHEMBL4741642 0.79 MAPT (0.64) MEN1KMT2AALDH1A1LMNAHTT
SCHEMBL22396176 0.79 MAPT (0.59) MEN1KMT2AMAPK10ALDH1A1LMNA
SCHEMBL4785451 0.79 MAPK1 (0.72) MEN1KMT2AALDH1A1LMNAHTT
SCHEMBL2943134 0.78 PDGFRB (0.63) MEN1KMT2AMAPK10ALDH1A1LMNA
SCHEMBL4742591 0.78 THRB (0.72) MEN1KMT2AMAPK10ALDH1A1LMNA
SCHEMBL25656123 0.77 MEN1 (0.55) MEN1KMT2AMAPK10ALDH1A1LMNA
SCHEMBL4742099 0.77 LMNA (0.55) MEN1KMT2AALDH1A1LMNAHTT
SCHEMBL4742104 0.77 MAPT (0.53) MEN1KMT2AMAPK10ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160152576-A9 AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA, INC. (US) 2016-06-02 US disclosed
US-20140148436-A1 AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA, INC. (US) 2014-05-29 US disclosed
US-8680114-B2 AKT protein kinase inhibitors ARRAY BIOPHARMA, INC. (US) 2014-03-25 US disclosed
US-20100168123-A1 AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168123-A1 AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT3 MEN1 2997/4885KMT2A 2166/4885MAPK10 103/4885
US-20140148436-A1 AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT3 MEN1 2997/4885KMT2A 2166/4885MAPK10 103/4885
US-20160152576-A9 AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT3 MEN1 2997/4885KMT2A 2166/4885MAPK10 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.